1800 Williams St., Suite 200 • Denver, CO 80218
Phone 303-388-4876 • Fax 303-336-2193 • Toll Free 1-800-891-7622

URL http://www.rockymountainbmt.com/news/Full-delivery-of-BEACOPP-14-chemotherapy-for-high-risk-Hodgkin-lymphoma-enabled-by-pegfilgrastim-support-966.html

Full delivery of BEACOPP-14 chemotherapy for high-risk Hodgkin lymphoma enabled by pegfilgrastim support

06-06-2006

Full dose delivery of BEACOPP-14 chemotherapy for high-risk Hodgkin lymphoma was enabled by pegfilgrastim support.

According to recent research published in the Haematologica - the Hematology Journal, "The primary endpoint of this feasibility study was to determine whether pegfilgrastim support could enable the delivery of the full dose of BEACOPP chemotherapy every 14 days on schedule. Forty-one patients with high-risk Hodgkin's lymphoma were randomized to receive pegfilgrastim (6 mg) on day 4 or 8 of each cycle."

"Eighty-one percent of cycles administered were delivered at full dose and on schedule (FDOS). Response was retrospectively assessed in 27 patients at 6 months; 23 of these 27 patients (85%) achieved a complete response and 1 (4%) achieved a partial response. Toxicities were mostly moderate in intensity," explained A. Engert and colleagues, University Hospital Cologne.

The researchers concluded, "These results support the feasibility of delivering full dose, on schedule BEACOPP-14, chemotherapy with pegfilgrastim support."

Engert and colleagues published their study in Haematologica - the Hematology Journal (Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Haematologica, 2006;91(4):546-549).

For additional information, contact A. Engert, University Hospital Cologne, Dept. Internal Medicine 1, Kerpener Str 62, D-50924 Cologne, Germany.

The publisher's contact information for the Haematologica - the Hematology Journal is: Ferrata Storti Foundation, Strada Nuova 134, 27100 Pavia, Italy.

Keywords: Cologne, Germany, Chemotherapy, Hematology, Hodgkin's Lymphoma, Oncology, Phase I, BEACOPP-14, Toxicities, Full Dose.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.